Bliss GVS Pharma Limited

Equities

BLISSGVS

INE416D01022

Pharmaceuticals

Delayed Bombay S.E. 01:44:17 2024-04-29 am EDT 5-day change 1st Jan Change
124.1 INR +1.22% Intraday chart for Bliss GVS Pharma Limited +7.40% -0.40%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Bliss GVS Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Bliss GVS Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Assistant Commission of State Tax Maharashtra, Mumbai Initiates Search At Certain Premises of Bliss GVS Pharma Limited CI
Bliss Gvs Pharma Limited Announces Change in the Designation of Mr. Vishal Vijay Rao CI
Bliss GVS Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Bliss GVS Pharma Limited Declares Final Dividend for the Financial Year Ended March 31, 2023 CI
Bliss GVS Pharma Gets Establishment Inspection Report from US FDA for Palghar, India Unit MT
Bliss Gvs Pharma Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023 CI
Bliss GVS Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Bliss GVS Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Infomerics Keeps BBB Rating on Bliss GVS Pharma's Bank Financing; Outlook Stable MT
Bliss GVS Pharma Gets Three Observations from US FDA's Plant Inspection in Maharashtra, India MT
Bliss GVS Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Bliss GVS Pharma Names New CFO MT
Bliss GVS Pharma Limited Appoints Mr. Deepak Sawant as Chief Financial Officer CI
Bliss GVS Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Bliss GVS Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Bliss GVS Pharma Limited Declares Final Dividend for the Financial Year Ended March 31, 2022 CI
Bliss GVS Pharma CFO Resigns MT
Bliss GVS Pharma Limited Announces Resignation of Mr. Vipul B. Thakkar as Chief Financial Officer CI
Bliss GVS Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022 CI
Bliss GVS Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2022 CI
Bliss GVS Pharma Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022 CI
Bliss GVS Pharma Forms New Subsidiary in Congo MT
Bliss GVS Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
Chart Bliss GVS Pharma Limited
More charts
Bliss GVS Pharma Limited is engaged in developing, manufacturing, and marketing pharmaceutical formulations. The Company’s product categories include pharma products and other healthcare products. Its pharma products include pharma products include capsules, creams, gels, ointments, dry powder for injection, effervescent tablets, eye/ear drops, nasal solution, lotions, lozenges, soft gelatine capsules and syrups. The Company’s other healthcare products include balm, nasal inhaler, solution, soap, vaginal wash, roll on, shampoo, powder, spray, and petroleum jelly. Its brands include ANOMEX, ANOMEX DS, CONLAX 5/10, G - ALFENAC 100, GACET 80/125/170/250/500/1G, GMETH - 50/100, GSUNATE - 50/100/200, GVCAM - 7.5/15, GV-SOFT 1/2/3/4 G, LOFNAC - 12.5/25/50/100, MEFINOL, MELANEZ, MENINA - 25/100, TYRIDOL, VIGOTAMIN, COMIT 50, BG - CLIND, VAGID CL, ECOZOLE, GVGYL 500, GYNANFORT, GVGYL N, KLOVINAL, LONART, LONART FORTE, LONART Dispersible, FINMOL, GACET-500, and DOXYCYCLINE.
More about the company
  1. Stock Market
  2. Equities
  3. BLISSGVS Stock
  4. News Bliss GVS Pharma Limited
  5. Infomerics Keeps BBB Rating on Bliss GVS Pharma's Bank Financing; Outlook Stable